// App-Quantinova.ai

: Eosinophils as a predictor of mepolizumab treatment responses in COPD

Researchers

Presenter

  • Ian Douglas Pavord

Principal Investigators

  • Gerard Criner

  • Huib Kerstjens

  • Eric Bradford

  • Stephanie Schweiker Harris

  • Oliver Keene

  • Bhabita Mayer

  • David Rubin

  • Steven Yancey

  • Daniel Bratton

Medical Centers

  • Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom,

  • Internal Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States,

  • Dept. of Pulmonary Diseases - University of Groningen and University Medical Center Groningen, Groningen, Netherlands

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, United States.

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

Locations

  • United Kingdom

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved